Arovella Therapeutics Ltd

E4NA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,970.5044.90-0.50%
CAC 407,861.964.600.06%
DAX 4024,262.2244.850.19%
Dow JONES (US)44,461.28171.71-0.38%
FTSE 1009,136.940.620.01%
HKSE25,176.93347.52-1.36%
NASDAQ21,129.6731.380.15%
Nikkei 22540,814.94160.240.39%
NZX 50 Index12,850.185.79-0.05%
S&P 5006,362.907.96-0.12%
S&P/ASX 2008,713.4043.00-0.49%
SSE Composite Index3,615.726.010.17%

Market Movers